Diagnosis and management of neuropsychiatric SLE

被引:212
作者
Hanly, John G. [1 ,2 ,3 ]
机构
[1] Capital Hlth, Div Rheumatol, Dept Med, Halifax, NS B3H 4K4, Canada
[2] Capital Hlth, Dept Pathol, Halifax, NS B3H 4K4, Canada
[3] Dalhousie Univ, Halifax, NS B3H 4K4, Canada
基金
加拿大健康研究院;
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; GLUTAMATE-RECEPTOR ANTIBODIES; EMISSION COMPUTED-TOMOGRAPHY; P-PROTEIN ANTIBODIES; RANDOMIZED CLINICAL-TRIAL; NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; MAGNETIC-RESONANCE; COGNITIVE FUNCTION; ANTIPHOSPHOLIPID ANTIBODIES;
D O I
10.1038/nrrheum.2014.15
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nervous system involvement in systemic lupus erythematosus ( SLE) can manifest as a range of neurological and psychiatric features, which are classified using the ACR case definitions for 19 neuropsychiatric syndromes. Approximately one-third of all neuropsychiatric syndromes in patients with SLE are primary manifestations of SLE-related autoimmunity, with seizure disorders, cerebrovascular disease, acute confusional state and neuropathy being the most common. Such primary neuropsychiatric SLE ( NPSLE) events are a consequence either of microvasculopathy and thrombosis, or of autoantibodies and inflammatory mediators. Diagnosis of NPSLE requires the exclusion of other causes, and clinical assessment directs the selection of appropriate investigations. These investigations include measurement of autoantibodies, analysis of cerebrospinal fluid, electrophysiological studies, neuropsychological assessment and neuroimaging to evaluate brain structure and function. Treatment involves the management of comorbidities contributing to the neuropsychiatric event, use of symptomatic therapies, and more specific interventions with either anticoagulation or immunosuppressive agents, depending upon the primary immunopathogenetic mechanism. Although the prognosis is variable, studies suggest a more favourable outcome for primary NPSLE manifestations compared with neuropsychiatric events attributable to non-SLE causes.
引用
收藏
页码:338 / 347
页数:10
相关论文
共 123 条
[1]   The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus [J].
Ainiala, H ;
Loukkola, J ;
Peltola, J ;
Korpela, M ;
Hietaharju, A .
NEUROLOGY, 2001, 57 (03) :496-500
[2]  
Ainiala H, 2001, ARTHRIT RHEUM-ARTHR, V45, P419, DOI 10.1002/1529-0131(200110)45:5<419::AID-ART360>3.0.CO
[3]  
2-X
[4]   Systemic lupus erythematosus in three ethnic groups.: X.: Measuring cognitive impairment with the cognitive symptoms inventory [J].
Alarcón, GS ;
Cianfrini, L ;
Bradley, LA ;
Sanchez, ML ;
Brooks, K ;
Friedman, AW ;
Baethge, BA ;
Fessler, BJ ;
Bastian, HM ;
Roseman, JM ;
McGwin, G ;
Reveille, JD .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (03) :310-319
[5]   Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus [J].
Appenzeller, Simone ;
Pike, G. Bruce ;
Clarke, Ann E. .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2008, 34 (03) :361-366
[6]   Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus [J].
Arinuma, Yoshiyuki ;
Yanagida, Tamiko ;
Hirohata, Shunsei .
ARTHRITIS AND RHEUMATISM, 2008, 58 (04) :1130-1135
[7]   Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus [J].
Barile-Fabris, L ;
Ariza-Andraca, R ;
Olguín-Ortega, L ;
Jara, LJ ;
Fraga-Mouret, A ;
Miranda-Limón, JM ;
de la Mata, JF ;
Clark, P ;
Vargas, F ;
Alcocer-Varela, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (04) :620-625
[8]   Mortality related to cerebrovascular disease in systemic lupus erythematosus [J].
Bernatsky, S. ;
Clarke, A. ;
Gladman, D. D. ;
Urowitz, M. ;
Fortin, P. R. ;
Barr, S. G. ;
Senecal, J-L ;
Zummer, M. ;
Edworthy, S. ;
Sibley, J. ;
Pope, J. ;
Ensworth, S. ;
Ramsey-Goldman, R. ;
Hanly, J. G. .
LUPUS, 2006, 15 (12) :835-839
[9]   EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs [J].
Bertsias, G. K. ;
Ioannidis, J. P. A. ;
Aringer, M. ;
Bollen, E. ;
Bombardieri, S. ;
Bruce, I. N. ;
Cervera, R. ;
Dalakas, M. ;
Doria, A. ;
Hanly, J. G. ;
Huizinga, T. W. J. ;
Isenberg, D. ;
Kallenberg, C. ;
Piette, J. C. ;
Schneider, M. ;
Scolding, N. ;
Smolen, J. ;
Stara, A. ;
Tassiulas, I. ;
Tektonidou, M. ;
Tincani, A. ;
van Buchem, M. A. ;
van Vollenhoven, R. ;
Ward, M. ;
Gordon, C. ;
Boumpas, D. T. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (12) :2074-2082
[10]   Devic's syndrome in a woman with systemic lupus erythematosus: Diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody [J].
Birnbaum, Julius ;
Kerr, Douglas .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (02) :347-351